Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728526 | 0.81 | BRD9 (0.59) | KMT2ALMNANPSR1L3MBTL1ALDH1A1 | |
| SCHEMBL19643639 | 0.78 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL19643237 | 0.75 | ROCK2 (0.63) | ROCK2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL15273031 | 0.70 | PPARA (0.52) | KMT2AMEN1 | |
| SCHEMBL30928898 | 0.69 | ALDH1A1 (0.67) | KMT2AMEN1LMNANPSR1ALDH1A1 | |
| SCHEMBL30928921 | 0.69 | ALDH1A1 (0.62) | KMT2AMEN1LMNANPSR1ALDH1A1 | |
| SCHEMBL13114749 | 0.68 | MAPT (0.40) | ROCK2KMT2ALMNANPSR1ALDH1A1 | |
| SCHEMBL10437994 | 0.68 | NPSR1 (0.70) | ROCK2KMT2AMEN1LMNANPSR1 | |
| SCHEMBL7821971 | 0.67 | KDM4E (0.53) | KMT2AMEN1LMNANPSR1L3MBTL1 | |
| SCHEMBL3523570 | 0.67 | L3MBTL1 (0.71) | ROCK2KMT2AMEN1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153663-B | Triazolones and tetrazolones as ROCK inhibitors | 百时美施贵宝公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464262-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885KMT2A 2199/4885MEN1 608/4885 |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885KMT2A 2199/4885MEN1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.